New insights on Multiple Sclerosis

The multiple sclerosis is a frequent cause of neurological disease arising in early to middle adulthood and has a complex etiology involving both genetic and environmental factors. To date, more than 100 variants that promote disease predisposition, alter disease penetrance and stochastic occurrences, have been identified. Despite the progress in identifying the genetic determinants of the disease, their phenotypic consequences remain to be elucidated, and a substantial understanding of environmental contributors is lacking. In summary, a better understanding of the pathological mechanisms is needed.

Two decades of clinical experience with immunomodulatory treatments point to distinct immunological pathways that drive disease relapses and progression. Although the drugs used to treat this complicated disease have an immunomodulatory effect and reduce the frequency of relapses, the trade-off of efficacy is a range of side effects, and the most common drugs approved for multiple sclerosis do not halt neurodegeneration, but they do delay the progression of the disease. The most prominent goal for future treatments is the targeting of relapses and progression, through combinatorial therapies that modulate both arms of the disease. Improved disease prognosis and potential patient stratification for more directed healthcare provision are also much-anticipated prospects and may become tangible.

There is so much left to do for the sclerosis multiple patients. Since the disease has a multifactorial cause, there are so many pathways involved in their progression, being more difficult the creation of more effective drugs. However, many pharmaceuticals have been focused in the development of the most effective therapy and we hope in a near future will be available for all patients at a more affordable coast, for example those that are in public institutions.

Here in Althian we have witnessed that some drugs that have been created for a determined disease, can work for a complete different one. Many pathways can be affected for these drugs and that’s why they can be used to treat related diseases. Please contact us and you will be able to see how much experience we have.